Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Cleveland BioLabs

Request full access

Focuses on developing therapies for cancer, inflammatory, autoimmune, and infectious diseases

Buffalo, United StatesFounded 2003Biotech & Life Sciences

About Cleveland BioLabs

Founded in June 2003 by Andrei V. Gudkov and Yakov Kogan, Cleveland BioLabs operated as a clinical-stage biopharmaceutical company headquartered in Buffalo, New York. The company focused on developing novel approaches to activate the immune system, with a primary concentration on oncology and the development of orphan drugs. Its business model revolved around the research, development, and eventual commercialization of proprietary products designed to treat cancer and mitigate the toxic effects of radiation and chemotherapy.

The company's core technology was a proprietary platform of Toll-like immune receptor (TLR) activators. Its flagship product candidate was Entolimod (CBLB502), a derivative of salmonella flagellin that acts as an agonist for Toll-like receptor 5 (TLR5). Entolimod was developed for a dual-use market: as a medical countermeasure to prevent death from acute radiation syndrome (ARS) and as an immunotherapy for oncology. For the ARS indication, the drug received both Fast Track and Orphan Drug status from the U.S. Food and Drug Administration. In oncology, preclinical studies showed Entolimod could suppress the growth of certain tumors and act as a supportive care agent when combined with radiation treatment. The company's pipeline also included Mobilan, a gene therapy agent, and CBL0137, a small molecule for cancer treatment.

Throughout its history, Cleveland BioLabs established strategic partnerships with institutions like the Cleveland Clinic and Roswell Park Cancer Institute. It also engaged in joint ventures, such as Incuron, LLC, and Panacela Labs, Inc., to advance its pipeline. A significant corporate milestone occurred in October 2020, when Cleveland BioLabs entered into a definitive merger agreement with Cytocom Inc. This all-stock, reverse merger transaction was completed on July 27, 2021, with the combined entity operating under the name Cytocom, Inc. The merger was positioned as a transformative event, creating a combined company with a broad pipeline focused on immune-modulating therapies for cancer, autoimmune diseases, and inflammatory conditions.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2003
Headquarters
Buffalo, United States
Listing
IPO 2006
Employees
22
Open positions
None listed
Dealroom signal
49.2/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, Cancer Care Companion, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
MERGER✓Other financing Jul 2021 — — Statera BioPharma ↗
POST IPO EQUITY✓Other financing Feb 2021 $14M — Undisclosed ↗
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Cleveland BioLabs website traffic

Latest recorded traffic for Cleveland BioLabs is 370 monthly website visits, up 1133.3% over the last three months. Cleveland BioLabs's team declined 4.3% over the past year.

Latest monthly visits370 3-month web change+1133.3% 1-year team growth-4.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Cleveland BioLabs in the Buffalo ecosystem

Live from Dealroom

The Cleveland BioLabs office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later3 investors entered at this stage

  • Hercules Capital
  • David Davidovich
  • Norma Investment

Other known investors3 additional known investors

Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States80%
🇬🇧 United Kingdom20%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Cleveland BioLabs on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Cleveland BioLabs’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.